First evaluation of the performance of portable IGRA, QIAreach® QuantiFERON®-TB in intermediate TB incidence setting
PLOS ONE · 2023
DOI: 10.1371/journal.pone.0279882 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS ONE, 2023. Verfasst von Zirwatul Adilah Aziz und 3 weiteren Autor:innen. Beteiligte Einrichtung: National Public Health Laboratory, Ministry of Health, Selangor, Malaysia. Hauptthemen laut MEDLINE: Tuberculosis, Latent Tuberculosis. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Long Term Research Grant, Ministry of Higher Education Malaysia, QIAGEN.
Abstract (Originalsprache)
Diagnosis and treatment of tuberculosis infection (TBI) are the core elements of tuberculosis elimination. Interferon gamma release assays have advantages over the tuberculin skin test, although their implementation in low-resource settings is challenging. The performance of a novel digital lateral flow assay QIAreach ® QuantiFERON ® -TB (QIAreach QFT) against the QuantiFERON ® -TB Gold Plus (QFT-Plus) assay was evaluated in an intermediate incidence setting (Malaysia) according to the manufacturer’s instructions. Individuals aged 4–82 years, who were candidates for TB infection screening for contact investigation were prospectively recruited. On 196 samples, the QIAreach-QFT showed a positive percent agreement (sensitivity) was 96.5% (CI 87.9–99.6%), a negative percent agreement (specificity) 94.2% (CI 88.4% to 97.6%) and an overall percentage of agreement was 94.9% (95% CI 90.6–97.6%) with a Cohen’s κ of 0,88. Out of 196, 5.6% (11/196) samples gave an error result on QIAreach-QFT and 4.1% (8/196) samples gave indeterminate result on QFT-plus. The TTR for QIAreach QFT positive samples varied from 210–1200 seconds (20 min) and significantly correlated with IFN-γ level of QFT-Plus. QIAreach QFT could be considered an accurate and reliable point-of-need test to diagnose TB infection helping to achieve the WHO End TB programme goals even in decentralised settings where laboratory expertise and infrastructure may be limited.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- National Public Health Laboratory, Ministry of Health, Selangor, Malaysia.
ORCID-Profile: Zirwatul Adilah Aziz
Förderung
- Long Term Research Grant
- Ministry of Higher Education Malaysia
- QIAGEN
Zitieren
APA
Aziz, Z. A., Noordin, N. M., Wan Mohd, W. M., & Kasim, M. A. (2023). First evaluation of the performance of portable IGRA, QIAreach® QuantiFERON®-TB in intermediate TB incidence setting. PLOS ONE. https://doi.org/10.1371/journal.pone.0279882
Vancouver
Aziz ZA, Noordin NM, Wan Mohd WM, Kasim MA. First evaluation of the performance of portable IGRA, QIAreach® QuantiFERON®-TB in intermediate TB incidence setting. PLOS ONE. 2023. doi:10.1371/journal.pone.0279882
BibTeX
@article{Aziz2023,
author = {Aziz, Zirwatul Adilah and Noordin, Noorliza Mohamad and Wan Mohd, Wan Mazlina and Kasim, Mohd Amin},
title = {First evaluation of the performance of portable IGRA, QIAreach® QuantiFERON®-TB in intermediate TB incidence setting},
journal = {PLOS ONE},
year = {2023},
doi = {10.1371/journal.pone.0279882}
}
EUVIMED